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Objective: The optimal procedure for resection of malignant pleural mesothelioma is
controversial, partly because previous analyses include small numbers of patients. We
performed a multi-institutional study to increase statistical power to detect significant
differences in outcome between extrapleural pneumonectomy and pleurectomy/
decortication.
Methods: Patients with malignant pleural mesothelioma who underwent extrapleural
pneumonectomy or pleurectomy/decortication at 3 institutions were identified. Sur-
vival and prognostic factors were analyzed by the Kaplan–Meier method, log-rank
test, and Cox proportional hazards analysis.
Results: From 1990 to 2006, 663 consecutive patients (538 men and 125 women)
underwent resection. The median age was 63 years (range, 26–93 years). The opera-
tive mortality was 7% for extrapleural pneumonectomy (n 5 27/385) and 4% for
pleurectomy/decortication (n 5 13/278). Significant survival differences were seen
for American Joint Committee on Cancer stages 1 to 4 (P, .001), epithelioid versus
non-epithelioid histology (P , .001), extrapleural pneumonectomy versus pleurec-
tomy/decortication (P , .001), multimodality therapy versus surgery alone (P ,
.001), and gender (P , .001). Multivariate analysis demonstrated a hazard rate of
1.4 for extrapleural pneumonectomy (P , .001) controlling for stage, histology,
gender, and multimodality therapy.
Conclusion: Patients who underwent pleurectomy/decortication had a better survival
than those who underwent extrapleural pneumonectomy; however, the reasons are
multifactorial and subject to selection bias. At present, the choice of resection should
be tailored to the extent of disease, patient comorbidities, and type of multimodality
therapy planned.
T
he role of surgical resection, especially extrapleural pneumonectomy (EPP), in
the management of malignant pleural mesothelioma (MPM) is controversial.
EPP usually involves an en bloc resection of lung, pleura, pericardium, and
diaphragm, whereas pleurectomy/decortication (P/D) involves resection of the parie-
tal and visceral pleurae, pericardium, and diaphragm when necessary, but spares the
lung. The goal of surgery is to remove all gross disease, but a complete resection (R0)
with surgery alone is theoretically unattainable because of the inability to eradicate
residual microscopic disease regardless of whether an EPP or P/D is performed.
Therefore, treatment has focused on surgery in combination with radiation and/or
chemotherapy in a multimodality setting.
The majority of studies have included exclusively either P/D or EPP in conjunction
with preoperative or postoperative chemotherapy, intrathoracic chemotherapy,
postoperative external beam radiotherapy, intensity-modulated radiation therapy,
intraoperative radiotherapy, brachytherapy, photodynamic therapy, and a number of
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other novel adjuvants.1-11 However, the decision to perform
either EPP or P/D in multimodality studies is based predom-
inantly on surgeon bias rather than scientific data.
Several studies have chosen end points, such as time to
progression and patterns of recurrence, to justify the pre-
ferred procedure because the numbers are too small to dem-
onstrate statistically significant differences in survival.12-14
However, these end points are fraught with inaccuracy be-
cause the follow-up practices, definitions of progression of
disease, and ways of documenting recurrence vary greatly.
Thus, rates of progression-free survival may differ consider-
ably from overall survival. Therefore, this study was under-
taken to investigate the outcomes of EPP and P/D with
overall survival as the primary end point.
Materials and Methods
All information on patients with biopsy-proven MPM who under-
went EPP and P/D between 1990 and 2006 was obtained and
analyzed under institutional review board approval at the Memorial
Sloan-Kettering Cancer Center, National Cancer Institute, and Kar-
amanos Cancer Institute. A common variable database was created.
Pathologic diagnosis was based on histology, immunohistochemical
analysis, and, when indicated, electron microscopy. Clinical data
were obtained from institutional databases, and variables recorded
included age, gender, histologic subtype, laterality, stage, asbestos
exposure history, surgical procedure, and multimodality treatment.
Staging was performed using the sixth edition of the AJCC Cancer
Staging Handbook.15 Pathologic stage was based on the patholo-
gist’s evaluation of the resected specimen and the surgeon’s intra-
operative findings. All patients were followed until the date of
death or the date of last follow-up if still alive. Dates of death
were verified through the Social Security Death Index and personal
telephone communications.
Treatment selection was based primarily on the tumor stage,
patients’ overall medical condition, and requirements of several pro-
spective clinical trials performed during this time period. Operative
intervention was recommended to patients with tumor localized to
the hemithorax by computed tomography scan and adequate cardio-
pulmonary function testing. Routine mediastinoscopy and magnetic
resonance imaging were not performed. Positron emission tomogra-
phy has only recently been used for clinical staging. EPP was
defined as an en bloc resection of the pleura, lung, ipsilateral
diaphragm, and pericardium. P/D removed tumor with the parietal
and visceral pleurae and pericardium and/or diaphragm when neces-
sary without removing the entire underlying lung. In patients not
participating in protocols that mandated either EPP or P/D, the
decision to perform an EPP or P/D was based on intraoperative find-
ings, tumor stage, patients’ medical condition, and surgeons’ intra-
operative judgment about which procedure would permit resectionThe Journal of Thorof all gross tumor. The decision to perform chemotherapy or radia-
tion was based on enrollment in a clinical trial. The total radiation
dose and method of administration was dependent on whether an
EPP or a P/D had been performed.16,17 When a patient could not
participate in a clinical trial, therapy was administered according
to protocol guidelines.
Statistical Methods
Comparison of proportions of prognostic variables in EPP and P/D
were assessed by the Pearson chi-square test. Operative mortality
included all patients who died within 30 days of surgery or during
the same hospitalization. Survival was calculated from the date of
surgery until the date of death or the date of last follow-up. Survival
and prognostic factors were analyzed by the Kaplan–Meier method,
and the log-rank test was used to assess statistical significance. A
Cox proportional hazard analysis was used to assess the joint influ-
ences of predictors on survival. Insignificant variables were then
excluded from the analysis using a stepwise procedure, thus yielding
the final model. The Stata 8 (Stata Corp, College Station, Tex)
statistical package was used.
Results
A total of 663 consecutive patients underwent surgical resec-
tion by either EPP or P/D (Memorial Sloan-Kettering Cancer
Center, n5 448; National Cancer Institute, n5 96; Karama-
nos Cancer Institute, n5 119). The clinical characteristics are
outlined in Table E1 and were typical of patients with MPM.
Patients were predominantly male and often gave a history of
asbestos exposure. Most tumors were of epithelioid histology
and were stages II or III at diagnosis. Approximately 60% of
patients underwent EPP. Operative mortality was 7% for EPP
(n5 27/385) and 4% for P/D (n5 13/278). A comparison of
the distribution of prognostic variables between patients un-
dergoing EPP and P/D are presented in Table 1. P/D had a sig-
nificantly greater proportion of patients who were several
years older with early stage tumors, whereas patients under-
going EPPweremore likely to receivemultimodality therapy,
have a higher proportion of epithelioid tumors, and have
a greater frequency of asbestos exposure. Postoperative com-
plications recorded according to the Common Terminology
Criteria for Adverse Events version 3.0 grading system are
outlined in Table E2. It was not surprising that the most com-
mon adverse events among patients undergoing EPP were
atrial arrhythmias and respiratory complications. Severe or
life-threatening (grades 3–5) respiratory complications oc-
curred in 10%of patients undergoingEPP. Serious respiratory
complications were less frequent after P/D, occurring in 6.4%
of patients, but were still the most common adverse event.
Patterns of recurrence are outlined in Table 2.
With a median follow-up of 17 months, the median
survival of all patients in this study was 14 months. Of the
663 patients, only 97 were censored, 47 of 97 (48.5%) who
underwent P/D and 50 of 97 (51.5%) who underwent EPP.
The overall survival at 5 years for all patients was 12%,
and the median survival was 38 months for stage I, 19 monthsacic and Cardiovascular Surgery c Volume 135, Number 3 621
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TSfor stage II, 11 months for stage III, and 7 months for stage IV
tumors (Figure E1). Univariate analyses showed that tumor
histologic subtype and stage, both commonly accepted prog-
nostic variables, were associated with highly significant
differences in survival, both with P values of less than .001
(Figures 1 and 2). Female gender (P, .001) and multimodal-
ity treatment (P , .001) were significantly associated with
improved survival. History of asbestos exposure demon-
strated a slightly improved survival for patients without
asbestos exposure (P 5 .06). Laterality and surgeon were
not significant.
By univariate analysis, EPP was associated with a signifi-
cantly worse survival than P/D (P , .001) (Figure 3), even
when operative deaths were excluded. An analysis of surgical
procedure in relationship to American Joint Committee on
Cancer tumor stage was performed to identify differences
in survival in favor of EPP versus P/D. There was no statis-
tical difference in survival by procedure at any individual
tumor stage (Figures 4–7). Only 14 patients underwent
EPP with stage IV disease (usually T4 tumors) with a median
survival of 4 months.
TABLE 1. Comparison of prognostic variables among
patients undergoing extrapleural pneumonectomy and
pleurectomy/decortication
EPP (n 5 385) P/D (n 5 278) P value
Age (mean) 60 y 63 y ,.001
Male gender 316 (82%) 220 (79%) .267
Epithelioid histology 269 (69%) 178 (64%) .090
Early stage (I 1 II) 96 (25%) 98 (35%) ,.001
Asbestos exposure 231 (60%) 149 (54%) .080
Laterality (right) 217 (56%) 173 (62%) .156
Multimodality therapy 266 (69%) 161 (58%) .002
EPP, Extrapleural pneumonectomy; P/D, pleurectomy/decortication.
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Figure 1. Overall survival of epithelioid versus non-epithelioid
tumor, by univariate analysis.622 The Journal of Thoracic and Cardiovascular Surgery c MarIn an analysis grouping larger numbers of patients by early
stage (stages I and II), there was also no significant difference
between EPP (n 5 96; 19 months) and P/D (n 5 98; 23
months, P 5 .07), even when operative deaths were
excluded; there was no significant difference by late stage
disease (stages III and IV, data not shown). In a multivariable
analysis by Cox proportional hazards model that controlled
for histology, stage, gender, and multimodality therapy,
EPP had a higher hazard ratio of 1.4 compared with P/D
(P , .001) (Table 3).
Discussion
The treatment of MPM remains controversial but has evolved
considerably during the past 16 years of this study. Advances
in the management of MPM include easier and more accurate
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Figure 2. Overall survival by American Joint Committee on Cancer
stage, by univariate analysis. AJCC, American Joint Committee on
Cancer.
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Figure 3. Overall survival of EPP versus P/D, by univariate
analysis. EPP, Extrapleural pneumonectomy; P/D, pleurectomy/
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TSmethods of pathologic diagnosis, improved methods of stag-
ing and selecting patients for surgery, a significant decrease
in operative mortality especially for EPP, marked improve-
ments in local control with combined resection and adjuvant
radiotherapy, and better systemic therapies3,6,18-24 These
changes have led to wide variations and considerable contro-
versy in the use of EPP or P/D for resection of MPM. Contro-
versy over EPP and P/D focuses on their relative merits with
respect to operative risk, ability to remove all gross tumor,
and options for adjuvant therapy. Proponents of EPP believe
that it more frequently allows a complete removal of all gross
tumor (R0/R1 resection), with increasingly acceptable rates
of morbidity and mortality, and facilitates the administration
of postoperative high-dose hemithoracic radiation, which in
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Figure 4. Overall survival of EPP versus P/D for patients with
stage I. EPP, Extrapleural pneumonectomy; P/D, pleurectomy/
decortication.
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Figure 5. Overall survival of EPP versus P/D for patients with
stage II. EPP, Extrapleural pneumonectomy; P/D, pleurectomy/
decortication.The Journal of Thoturns provides excellent local control.6 Proponents of P/D
believe that it provides adequate cytoreduction, especially
for patients with earlier stage tumors, is associated with
a lower morbidity and mortality than EPP, and is an effective
part of a multimodality treatment program in conjunction
with therapies such as photodynamic therapy, intrapleural
or systemic chemotherapy, and intensity-modulated radiation
therapy.1,2,4-6,10,11
Our results in this study reflect all of the pros and cons and
the controversies surrounding the use of EPP and P/D. In a pa-
tient population who are typical for MPM (given age, gender,
tumor stage, and histology), our decision to perform an EPP
or P/D was based on a combination of factors, including
patient operative risk, technical ability to remove all gross
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Figure 6. Overall survival of EPP versus P/D for patients with
stage III. EPP, Extrapleural pneumonectomy; P/D, pleurectomy/
decortication.
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Figure 7. Overall survival of EPP versus P/D for patients with
stage IV. EPP, Extrapleural pneumonectomy; P/D, pleurectomy/
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mandated performing either one operation or the other.
Although our study is retrospective, it benefits from being
multicenter and including a larger number of patients than
other surgical series, and therefore has a greater statistical
power to identify potential survival differences between
EPP and P/D. Our results confirm previous smaller studies
with respect to the lower mortality of P/D, differences in post-
operative adverse events, and patterns of relapse. Patients
who undergo EPP and adjuvant therapy, particularly high-
dose hemithoracic radiation, relapse predominantly in distant
sites, whereas after P/D disease progression occurs predom-
inantly locally in the ipsilateral hemithorax.1,2,4-6,16 Any
clinician who treats patients with MPM is well aware of these
differences in disease progression that lead to notable differ-
ences in patient symptoms during the latter phases of their
disease. Local disease progression after P/D leads to death
from worsening restrictive lung disease, intractable chest
pain, and respiratory failure. Distant disease progression,
usually after EPP, manifests most frequently with dyspnea
from a contralateral pleural effusion, ascites, or both.
The relative impact of EPP and P/D on overall survival is
less clear. The results of our univariate analyses suggesting
a strong survival benefit for P/D become only marginally
TABLE 2. Site of first recurrence after extrapleural
pneumonectomy versus pleurectomy/decortication
EPP (n 5 219) n (%) P/D (n 5 133) n (%)
Local recurrences 73 (33%) 86 (65%)
Ipsilateral chest 68 (31%) 84 (63%)
Pericardium 5 (2%) 2 (2%)
Distant recurrences 146 (66%) 47 (35%)
Contralateral lung/pleura 49 (22%) 14 (11%)
Peritoneum 57 (26%) 24 (18%)
Peritoneum 1 chest 17 (8%) 1
Abdominal viscera 12 (5%) 4 (3%)
Bone 7 (3%) –
Brain 1 1
Cutaneous (distant) 1 1
Other 2 2 (2%)
EPP, Extrapleural pneumonectomy; P/D, pleurectomy/decortication.
TABLE 3. Multivariate analysis of prognostic variables that
were significant by univariate analysis
Hazard ratio Confidence interval P value
Age 1.0 (1.01–1.02) P , .001
Female gender 1.3 (1.05–1.64) P 5 .02
EPP 1.4 (1.18–1.69) P , .001
Non-epithelioid 1.3 (1.11–1.60) P , .001
Stage III/IV 1.4 (1.28–1.55) P , .001
Multimodality therapy .45 (0.38–0.54) P , .001
EPP, Extrapleural pneumonectomy.624 The Journal of Thoracic and Cardiovascular Surgery c Masignificant (hazard ratio 5 1.4) when considered in a multi-
variable analysis that accounts for other important variables,
such as tumor stage, histology, gender, and multimodality
treatment. This emphasizes the importance of considering
surgical data within the context of known prognostic factors.
Viewed from the most nihilistic perspective, these results
could be interpreted as indicating that neither approach to re-
section influences overall survival that is primarily dependent
on tumor histology, stage, nonsurgical therapy, and various
still undefined biological factors. Previous series and clinical
trials argue against this perspective,1-3,6 but ultimately this
question may be answered by a randomized clinical trial cur-
rently under way in the United Kingdom that addresses the
survival benefit of EPP relative to nonsurgical therapy.
Viewed from another perspective, our results could be inter-
preted as emphasizing the lack of truly effective systemic
therapy for MPM. For instance, patients who underwent
EPP who receive adjuvant hemithoracic radiation have
a low risk of local recurrence but currently have no available
systemic therapy that significantly reduces the risk of distant
metastases.1,2,6,14 No matter what the efficacy of EPP or P/D
in removing gross tumor, the lack of highly effective
adjuvant therapy for both of these operations leads to similar
results in terms of overall survival. By contrast, locally
advanced ovarian cancer, which is currently managed with
a combination of vigorous surgical cytoreduction and adju-
vant chemotherapy, is potentially curable, not only because
of the proven benefits of resection but also because of the
effectiveness of current chemotherapy for that disease.
Our study suffers from a lack of comorbidity data.
Although patients undergoing EPP are more likely to have
less comorbid disease than those undergoing P/D, this bias
would tend to falsely inflate survival results in the EPP group.
Selection bias plays a large role in determining who receives
EPP or P/D on the basis of intraoperative findings. There are
probably unmeasurable differences in the extent of disease
not accounted for in the staging system that may make the
tumor stage in patients undergoing EPP even more advanced
within the same stage, thus falsely favoring survival in the P/
D group. In addition, the ability of patients to undergo adju-
vant therapy is biased based on their postoperative functional
status, which, per se, would account for the differences in sur-
vival between patients undergoing multimodality therapy
versus patients undergoing surgery alone. This finding would
tend to favor EPP because 69% of patients receiving EPP
underwent multimodality therapy compared with 58% of
patients receiving P/D. Regardless of controlling for all
known biases, the data by its retrospective nature are limited
and the influence of unknown confounding variables cannot
be accounted for short of a randomized trial.
Conclusions
Our study emphasizes the similarities in outcome after EPP
or P/D for MPM in a multicenter setting and do not allowrch 2008
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TSus to advocate clearly for either one or the other surgical
approach at the current time. Pending the development of
more effective multimodality therapy, careful patient selec-
tion for both EPP and P/D on the basis of the cardiopulmo-
nary function, extent of the tumor, and ability to resect all
gross disease remains key to offering patients good treatment
with acceptable risk. Given the limitations that EPP and P/D
impose on the options for adjuvant therapy, we believe that
the choice of surgical procedure must also take into account
for each patient a multidisciplinary decision about the use of
nonsurgical therapies. Finally, our results emphasize the need
for additional well-designed prospective trials that address
the impact of these surgical procedures on outcome and pat-
terns of relapse within the context of multimodality therapy.
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Discussion
Dr D. Sugarbaker (Boston, Mass). It now seems that aggressive
surgical resection by EPP or P/D has an established role for treating
MPM particularly, and I think exclusively, in patients whose disease
is confined to the hemithorax. As you pointed out, there continues to
be controversy and, I would suggest, confusion over whether EPP or
P/D is a better operation. I have argued previously that achieving
a macroscopic complete resection (MCR) is the goal, as you have
suggested here as well, of mesothelioma surgery, whichever proce-
dure is used.
When comparing outcome for these procedures, one needs to be
mindful of the other prognostic factors that you have reviewed here
that affect survival. The principal factor, of course, is cell type, with
pure epithelial tumors behaving better in all published series than the
mixed or sarcomatous lesions. In addition, N2 node status, as re-
ported by our group at the Brigham, and disease bulk, as reported
by Harvey Pass, are significant prognostic factors. Particularly
when one considers bulk disease, as you have suggested, EPP is
many, many times the only operation where an R0 or MCR can be
achieved. I would therefore urge cautious interpretation of survival
comparisons between patients receiving P/D or EPP who do not at
least demonstrate a balance in these important prognostic factors.acic and Cardiovascular Surgery c Volume 135, Number 3 625
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gested, that non-epithelial MPM represents a distinct clinical entity
that should be examined and reported separately from epithelial
MPM. These subgroups of patients are different, their clinical course
is dramatically different, and it may be that their therapies eventually
become diverse as well.
So I have a couple of questions for you, Dr Flores. I think you
would agree that the appropriate operation in the setting of MPM
is the one most likely to result in an MCR. In many cases this deter-
mination is made at thoracotomy, and appropriately, early disease is
commonly resected by P/D when it appears that an MCR can be
achieved. As you pointed out in your study, 15% of the patients re-
ceiving P/D had stage I compared with only 3% of the patients re-
ceiving EPP. Bulky disease, which has been identified by Harvey
Pass as an indicator of poor prognosis, is more likely to be ap-
proached by EPP in terms of obtaining an MCR, and it remains un-
clear whether the type of surgical resection can actually affect the
prognosis when bulk disease has driven metastatic deposits, as
you have also shown here. Could these appropriate clinical differ-
ences in terms of bulk and cell type account for the survival differ-
ence you observed in the 2 procedures?
Dr Flores. Absolutely. I don’t think that these 2 procedures are
interchangeable. You don’t know what procedure you are going to
do until you get in there at the time of thoracotomy. That is why any
comparison that says the outcome is the same, why not just do a P/D
because you are sparing the lung? The point is if you have experi-
ence in mesothelioma surgery, you realize you can’t get most of
them out without doing an EPP. It is an intraoperative decision.
That is why there were so few EPP procedures in the patients with
stage I, because you just can’t compare it. It depends more on the
T stage. There are some pleurectomies in the stage III disease, and
those are usually patients who had N2 disease. If you have big bulky
tumor, you need an EPP, period.
Dr Sugarbaker. Given the prognostic importance of N2 that we
have demonstrated at the Brigham and your group at Memorial has
also demonstrated, at the Brigham now we are routinely performing
mediastinoscopy on patients presenting withMPM. Could you com-
ment on whether you have used this and on what you believe is the
most effective adjuvant therapy? Because MCR by either procedure
is the surgeon’s goal, how do we complete the therapy? What are
your current thoughts about what the best adjuvant treatment is?
Dr Flores. That is a point of controversy as well, what is the best
type of adjuvant therapy, and that definitely depends on the type of
procedure that you perform. If you perform an EPP and you remove
all gross disease, you don’t have the lung in place, so you can the-
oretically really crank up the radiation. At our institution we go
up to 5400 rads to really cook that chest to get the residual macro-
scopic disease. Now, those are the best results that we have obtained
in achieving local control.626 The Journal of Thoracic and Cardiovascular Surgery c MaFor P/D, some have tried intraoperative radiotherapy, others
have tried intrapleural chemotherapy. The type of resection that
you perform dictates your adjuvant therapy.
DrM. Krasna (Towson, Md). Your group, and ours, took part in
a prospective trial using trimodality therapy for treating patients
with mesothelioma. I understand the comparison if surgery alone
was all that we are advocating. However, there are now good data
that the combination of at least adjuvant and perhaps neoadjuvant
therapy, including, for instance, chemotherapy with pemetrexed
(Alimta, Eli Lilly and Co, Indianapolis, Ind) and/or cisplatinum,
might actually have a better result both in terms of survival and com-
plete resection. Would you comment on specifically the question of
an extrapleural versus a decortication in the context of patients who
receive neoadjuvant therapy?
Dr Flores. I think as far as multimodality therapy is concerned,
when you look at these patients in this study and you compare those
who had multimodality therapy versus those who did not, there is
a survival benefit for those who had multimodality therapy. Of
course, that is a very biased group, because the patients who went
on to receive adjuvant therapy had better performance status.
When you consider the patients who had induction therapy, and
we had a phase II trial that showed that, and DrWeder from Switzer-
land also had a trial that showed that, the preliminary results are en-
couraging: a 23-month median survival in patients who underwent
resection, even a 38-month median survival. We have looked at it
in the setting of EPP. No one has really looked at induction therapy
in the setting of pleurectomy. That is an area still ripe for investiga-
tion.
DrW.Weder (Zurich, Switzerland). The survival curve after the
2 procedures goes more or less in parallel after a few months of sur-
gery. The main difference in survival between the 2 procedures oc-
curs in the early weeks or months, and because the perioperative
mortality is almost the same with 3% and 7%, I would like to
know how you explain this. Why is the early survival between the
2 groups so different?
Dr Flores.That is an excellent question, and we looked into that.
We performed this same analysis on patients after operative mortal-
ity was excluded, and the results were the same. What I think is go-
ing on, when you look at the patients with stage IV, the median
survival of the extrapleurals is 4 months. I think that is what brings
the curve down at the beginning.
Dr R. Bueno (Boston, Mass). You showed us that lymph node
status has a major impact on survival in a large cohort of patients
with mesothelioma. Did you include the lymph node status in the
multivariate analyses and did lymph node positivity affect any of
the results?
Dr Flores. We did a multivariable analysis including lymph
node status, gender, surgeon, basically those variables, and there
was no difference.rch 2008
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Figure E1. Overall survival of all 663 patients in this study.G
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TSTABLE E1. Clinical characteristics of 663 patients in this
study
n (%)
Median age 63 y (range 26–93 y)
Men 536 (81%)
Women 127 (19%)
Laterality
Right 390 (59%)
Left 273 (41%)
History of asbestos exposure 380 (57%)
Histology
Epithelioid 447 (67%)
Non-epithelioid 216 (33%)
AJCC stage
I 52 (8%)
II 142 (21%)
III 411 (62%)
IV 58 (9%)
Surgery
EPP 385 (58%)
P/D 278 (42%)
Adjuvant therapy
Chemotherapy* 186 (28%)
Radiotherapy 152 (23%)
Both 89 (14%)
AJCC, American Joint Committee on Cancer; EPP, extrapleural pneumonec-
tomy; P/D, pleurectomy/decortication. *Includes preoperative chemo-
therapy, postoperative chemotherapy, intrapleural chemotherapy, and
tetrathiomolybdate.626.e2 The Journal of Thoracic and Cardiovascular Surgery c March 2008
Flores et al General Thoracic SurgeryTABLE E2. Postoperative adverse events recorded according to Common Terminology Criteria for Adverse Events 3.0*
Complications of EPP (n 5 385)
Complication Grade 1 (mild) Grade 2 (moderate) Grade 3 (severe) Grade 4 (disabling) Grade 5 (death)
Atrial arrhythmia 66 (17.1%)
Hemorrhage 3 1
Cardiac herniation 1
Deep venous thrombosis 3
Empyema 2 12 1
Gastrointestinal 3 1 1
Respiratoryy 17 (4.4%) 8 (2%) 14 (3.6%)
Pulmonary embolus 3 3
Multiorgan failure 2
Myocardial infarction 2 2
Ventricular arrhythmia 2 1 2
Urinary tract infection 2
Complications of PD (n 5 278)
Complication Grade 1 (mild) Grade 2 (moderate) Grade 3 (severe) Grade 4 (disabling) Grade 5 (death)
Atrial arrhythmia 13 (4.7%)
Hemorrhage 1
Deep venous thrombosis 1
Gastrointestinal 1
Prolonged air leak 10 (3.6%)
Respiratoryy 7 (2.5%) 1 (0.3%) 10 (3.6%)
Pulmonary embolus 1
Multiorgan failure 1
Myocardial infarction 1
Ventricular arrhythmia 1
Urinary tract infection 1
EPP, Extrapleural pneumonectomy; P/D, pleurectomy/decortication. *CTCAE, National Cancer Institute; Common Terminology Criteria for Adverse Events v.3.0.
Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf). 2006. yRespiratory complications include pneumonia, atelectasis, adult respiratory distress
syndrome, and pulmonary edema.G
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